Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Yum! Brands, Inc. (YUM) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Yum! Brands, Inc.Trade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Yum! Brands, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Yum! Brands, Inc. trades at $158.18 (market cap $43.60B). The key difference: Yum! Brands, Inc. is far larger — about 5.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Yum! Brands, Inc. pays a 1.9% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOYUM
Market Cap
$8.04B$43.60B
Sector
HealthConsumer Cyclical
52-Week High
$339.75$168.16
52-Week Low
$241.71$138.21
Enterprise Value
$7.85B$54.86B
Dividend Yield
1.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

Yum! Brands, Inc.

YUM Brands trades at $161.69, down 1.13% today, with a bullish technical signal from moving averages and key resistance at $163. The company reported Q1 2026 EPS of $1.50, beating expectations, while revenue grew to $8.21B in 2025. Recent news includes a Taco Bell health investigation and the $2.7B Pizza Hut sale, which may streamline operations.

YUM's outlook is supported by strong cash flow and margin stability, but high debt and competitive pressures pose risks. Analysts maintain a $174.60 price target with a mixed buy/hold consensus. The stock offers growth potential post-Pizza Hut divestiture, though investor sentiment is cautious amid near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Yum! Brands, Inc.

Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.

Read more on YUM